Results 211 to 220 of about 896,459 (312)
CSF Biomarker‐Based Cognitive Trajectories in Parkinson's Disease‐Subjective Cognitive Decline
ABSTRACT Objective Cognitive complaints without objective cognitive impairment in Parkinson's Disease, termed Parkinson's Disease‐Subjective Cognitive Decline (PD‐SCD), have been associated with cognitive decline. However, its progression is heterogeneous, highlighting the need for improved identification of patients at greater risk for deterioration ...
Jon Rodriguez‐Antiguedad+7 more
wiley +1 more source
Mechanistic Insights into Cytokine Antagonist-Drug Interactions: A Physiologically Based Pharmacokinetic Modelling Approach with Tocilizumab as a Case Study. [PDF]
Pan X+5 more
europepmc +1 more source
SARS‐CoV‐2 Is Linked to Brain Volume Loss in Multiple Sclerosis
ABSTRACT Objective The impact of SARS‐CoV‐2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS‐CoV‐2 infection.
Tomas Uher+12 more
wiley +1 more source
Polypharmacy, drug-drug interactions and adverse drug reactions in older Chinese cancer patients: evidence from CHARLS. [PDF]
Yan Z, Fan KQ, Yu T, Su N, Zou Y, Xia L.
europepmc +1 more source
ABSTRACT Objective Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for ...
Fortunata Carbone+19 more
wiley +1 more source
South African Dietitians' Knowledge and Perceptions of Food-Drug Interactions and Factors Affecting It. [PDF]
Megaw C, Olivier N, Cordier W.
europepmc +1 more source
Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan+8 more
wiley +1 more source